HemeRX

HemeRx is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of hematological disorders, specifically sickle cell disease and beta-thalassemia. Founded on research from the University of Chicago, the company specializes in the induction of fetal hemoglobin (HbF) to compensate for defective adult hemoglobin in patients. Their lead programs utilize proprietary small molecules designed to be orally bioavailable and disease-modifying, aiming to reduce vaso-occlusive crises and improve overall quality of life. HemeRx leverages deep expertise in erythropoiesis and molecular biology to advance its pipeline of HbF inducers through early-stage development.